Proteo, Inc. is a Nevada corporation; our common stock is quoted on the OTCQB under the symbol PTEO. The company has one wholly owned subsidiary, Proteo Biotech AG, a German corporation located in Kiel.
Proteo is a clinical stage drug development company and intends to develop, promote and market pharmaceuticals and other biotech products. The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs.
